B-type Natriuretic Peptide Assay in Differentiating Congestive Heart Failure from Lung Disease in Patients Presenting...

Area of Science:

• Cardiology
• Pulmonology
• Biomarker Research

Background:

• Dyspnea (shortness of breath) is a common symptom with overlapping causes, including congestive heart failure (CHF) and pulmonary disease.
• Accurate differentiation is crucial for appropriate patient management and treatment.
• B-type natriuretic peptide (BNP) is a hormone released by the heart in response to stretching, often elevated in heart failure.

Purpose of the Study:

• To evaluate the diagnostic utility of B-type natriuretic peptide (BNP) in differentiating congestive heart failure (CHF) from pulmonary disease in patients presenting with dyspnea.
• To compare BNP concentrations between patients diagnosed with CHF and those with pulmonary disease.

Main Methods:

• A cross-sectional study involving 100 dyspnic patients admitted to Cardiology & Medicine departments.
• Patients were diagnosed with either Congestive Heart Failure (CHF) using Framingham criteria or pulmonary disease using specific diagnostic tools.
• B-type natriuretic peptide (BNP) concentrations were measured and compared between the two groups.

Main Results:

• Patients diagnosed with CHF (n=50) exhibited significantly higher mean BNP levels (1146.72 pg/ml) compared to patients with pulmonary disease (n=50) (34 pg/ml) (p<0.05).
• The range of BNP levels in the CHF group was 103-5000 pg/ml, while in the pulmonary disease group it was 10-90 pg/ml.
• The study sample was predominantly male (94%).

Conclusions:

• B-type natriuretic peptide (BNP) serves as a valuable biomarker for differentiating congestive heart failure (CHF) from lung disease in patients experiencing dyspnea.
• Elevated BNP levels strongly suggest a cardiac origin of dyspnea, aiding clinical decision-making.